CellSeed

CellSeed Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of CellSeed (7776.T) as of Nov 1, 2026 is 699.30. In the previous year, Cash Conversion Cycle (CCC) was 244.81 — a change of 185.66% (higher).

Cash Conversion Cycle

699.30

YoY

185.66%

Last updated:

Cash Conversion Cycle (CCC) of CellSeed is 2025 699.30 . Cash Conversion Cycle (CCC) of CellSeed was 2024 244.81 . It decreases by 185.66% higher compared to the previous year.

The CellSeed Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
691.63 JPY
Jan 1, 2019
314.56 JPY
Jan 1, 2020
309.98 JPY
Jan 1, 2021
235.25 JPY
Jan 1, 2022
385.64 JPY
Jan 1, 2023
286.14 JPY
Jan 1, 2024
244.81 JPY
Jan 1, 2025
699.30 JPY
The CellSeed Cash Conversion Cycle history
YEARCash Conversion CycleYoY
699.30+185.66%
244.81-14.44%
286.14-25.80%
385.64+63.93%
235.25-24.11%
309.98-1.46%
314.56-54.52%
691.63+109.71%
329.80-54.50%
724.86+557.18%
110.30-32.38%
163.11—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

Cash Conversion Cycle (CCC) of CellSeed is 699.30 in 2025.

Cash Conversion Cycle (CCC) of CellSeed changed from 244.81 to 699.30, representing a 185.66% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) CellSeed since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s CellSeed with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CellSeed

All Key Metrics — CellSeed